Shop By
目录号
产品名
应用
产品描述
文献引用
-
AKT Inhibitor
MK-2206 2HCl 是一种高度选择性的 Akt1/2/3 抑制剂,其 IC50 分别为 8 nM/12 nM/65 nM。- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Yi-Ru Pan, .et al. , Int J Biol Sci, 2023, May 21;19(9):2772-2786 PMID: 37324940
- Giorgio Caratti, .et al. , EMBO Rep, 2023, Feb 6;24(2):e55363 PMID: 36520372
- Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
- Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
- Majid Momeny, .et al. , Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Ali Nasrollahzadeh, .et al. , Biochim Biophys Acta Mol Cell Res, 2021, Jun 26;1868(10):119087 PMID: 34182011
- Rona Aviram, .et al. , PLoS Biol, 2021, Dec 30;19(12):e3001492 PMID: 34968386
- Cristina Rosell??-Busquets, .et al. , Front Mol Neurosci, 2020, 13: 56 PMID: 32317932
- Dai-Chi Liu, .et al. , eNeuro, 2020, Mar 27;7(2):ENEURO.0438-19.2020 PMID: 32161037
- Nishihama K, .et al. , Metabolism, 2018, May;82:88-99 PMID: 29366755
- J Wei, .et al. , bioRxiv, 2018, 2018
- Joo Sang Lee, .et al. , Nat Commun, 2018, 9: 2546 PMID: 29959327
- Wan-Ting Hu, .et al. , Am J Cancer Res, 2018, 8(9): 1739-1751 PMID: 30323967
- Angela M. Gocher, .et al. , J Biol Chem, 2017, Aug 25; 292(34): 14188-14204 PMID: 28634229
- Kusuyama J, .et al. , Biochem J, 2017, Oct 5;474(20):3421-3437 PMID: 28887384
- Pi-Lin Sung, .et al. , Oncotarget, 2016, Jan 26; 7(4): 4036-4047 PMID: 26716408
- Mikaël M. Martino, .et al. , Nat Commun, 2016, 7: 11051 PMID: 27001940
- Dominik Schulz, .et al. , Am J Cancer Res, 2016, 6(9): 1963-1975 PMID: 27725902
- Jewett KA, .et al. , J Neurochem., 2015, Oct;135(2):226-33 PMID: 26250624
-
PI3K inhibitor
AZD6482 是一种 PI3Kbeta 抑制剂(IC50=0.021M),用于抗血栓治疗。- Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
-
mTOR Inhibitor
AZD8055 是一种强效、选择性且可口服生物利用度的 ATP 竞争性 mTOR 激酶抑制剂,其 IC50 为 0.8 nM。- L. M. C. Koene, .et al. , ACTN, 2019, June PMID: 31353861
- Helga Weber, .et al. , Oncotarget, 2015, Oct 13; 6(31): 31877-31888 PMID: 26397134
- Kentaro Hirose, .et al. , BMC Dev Biol, 2014, 14: 42. PMID: 25480380
-
PI3K/mTOR Inhibitor
BEZ235(NVP-BEZ235)通过结合到这些酶的ATP结合裂隙,抑制PI3K和mTOR激酶活性。- Lijuan Chen, .et al. , Behav Neurol, 2023, May 9;2023:6991826 PMID: 37200987
- Makoto Koyama, .et al. , Int J Oncol, 2020, Sep 2 PMID: 32901840
- Tzeng SF, .et al. , FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
- Dominik Schulz, .et al. , Am J Cancer Res, 2016, 6(9): 1963-1975 PMID: 27725902
-
PI3K inhibitor
CAL-101 是一种选择性抑制 PI3K 的异构体抑制剂,能够诱导慢性淋巴细胞性白血病(CLL)细胞的凋亡。- Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
- Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
- Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
- Yoshihiro Umezawa, .et al. , J Biol Chem, 2017, Dec 1; 292(48): 19639-19655 PMID: 28974577
-
GSK-3 Inhibitor
CHIR99021 是一种氨基嘧啶衍生物,能够抑制 GSK3α 和 GSK3β,其 IC50 值分别为 10 nM 和 6.7 nM。- Peilin Li, .et al. , Ecotoxicol Environ Saf, 2024, Dec:288:117330 PMID: 39571255
- Peilin Li, .et al. , Stem Cell Res Ther, 2024, Aug 26;15(1):269 PMID: 39183353
- Andreea Manole, .et al. , Cell Rep, 2023, Dec 26;42(12):113466 PMID: 38039131
- Claudia Z Han, .et al. , Immunity, 2023, Sep 12;56(9):2152-2171 PMID: 37582369
- Eric Lian, .et al. , STAR Protoc, 2023, May 22;4(2):102314 PMID: 37220001
- Tomoki Murata, .et al. , Int Immunol, 2023, Apr 13 PMID: 37052267
- Shunsuke Murakami, .et al. , Regen Ther, 2022, Nov 25;21:574-583 PMID: 36475025
- Adam Pietrobon, .et al. , Cell Rep, 2022, Jul 5;40(1):111048 PMID: 35793620
- Takayuki Miyoshi, .et al. , J Gastroenterol, 2022, Jun;57(6):441-452 PMID: 35294680
- Tomoki Kamatani, .et al. , Inflamm Regen, 2022, Feb 2;42(1):4 PMID: 35105370
- Dan Zhao, .et al. , Poult Sci, 2022, Mar; 101(3): 101642 PMID: 35016046
- Otsuka R, .et al. , Sci Rep, 2020, Jan 14;10(1):224 PMID: 31937817
- Yu Huang, .et al. , Stem Cells Int, 2019, 2019: 3975689 PMID: 31565060
-
mTOR Inhibitor
Deforolimus(Ridaforolimus)是一种处于研究阶段的靶向性小分子抑制剂,其作用目标是蛋白质 mTOR。通过阻断 mTOR,可以在癌细胞中产生类似饥饿的效果,这种效果通过干扰细胞的生长、分裂、代谢和血管生成来实现。 -
mTOR inhibitor
Everolimus(RAD-001)是西罗莫司的40-O-(2-羟乙基)衍生物,其作用方式与西罗莫司类似,均为mTOR抑制剂。- Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
- Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
- Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
- Gabriela Torres-Flores, .et al. , Adv Polym Technol, 2020, ID 5462949
- Takaaki Fujimura, .et al. , Cancer Biol Ther, 2020, Sep 1;21(9):863-870 PMID: 32835580
- BD Henriksbo, .et al. , Am J Physiol Endocrinol Metab, 2020, Jul 1;319(1):E110-E116 PMID: 32421368
- Hiroshi Fukamachi, .et al. , J Exp Clin Cancer Res, 2019, 38:127 PMID: 30866995
- Nachi Namatame, .et al. , Oncotarget, 2018, Oct 12; 9(80): 35141-35161 PMID: 30416685
- Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Rieko Ohki, .et al. , Proc Natl Acad Sci U S A, 2014, 111(23): E2404-E2413 PMID: 24912192
-
mTOR inhibitor
FK-506 是一种免疫抑制药物,主要用于异体器官移植后,通过降低患者免疫系统的活性,从而减少器官排斥的风险。它通过减少 T 细胞产生的白细胞介素-2 (IL-2) 来发挥作用。- Ogawa Y, .et al. , Neurobiol Dis, 2018, Oct;118:142-154 PMID: 30026035
- Yuko Okamoto, .et al. , J Drug Deliv Sci Technol, 2018, 47: 62-66
-
PI3K inhibitor
GDC-0941 是一种强效、选择性、口服生物利用度的 class I PI3 kinase (PI3K) 抑制剂,其 IC50 值(纳摩尔)分别针对 p110 α、β、δ 和 γ 亚型、DNA-PK 和 mTOR 为 3、33、3、75、1230 和 580。- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
- Joo Sang Lee, .et al. , Nat Commun, 2018, 9: 2546 PMID: 29959327
-
mTOR/PI3K Inhibitor
GSK1059615 是一种强效的、可逆的、ATP竞争性的、噻唑烷二酮类抑制剂,针对 PI3Kα(IC50 = 2 nM)。- Jing Xie, .et al. , Oncotarget, 2017, Aug 1; 8(31): 50814-50823 PMID: 28881606
-
mTOR Inhibitor
KU-0063794 是一种选择性的哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂(对 mTORC1 和 mTORC2 的 IC50 均约为 10 nM)。 -
ATM inhibitor
KU-55933 是一种 ATM 抑制剂,通过抑制细胞增殖并通过阻断在癌细胞中过度激活的 Akt 来诱导凋亡。- Ryo Sakasai, .et al. , Biochem Biophys Res Commun, 2023, Aug 6;668:42-48 PMID: 37244033
- Atsushi Saito, .et al. , Cell Rep, 2023, May 30;42(5):112479 PMID: 37178686
- Mariko Shikata, .et al. , Chem Res Toxicol, 2021, Dec 20;34(12):2512-2521 PMID: 34784199
- Masaya Igase, .et al. , Mol Ther Oncolytics, 2019, vol 15 PMID: 31650025
- Hayakawa K, .et al. , Biochem Biophys Res Commun, 2018, Dec 2;506(4):983-989 PMID: 30404732
- Chwastek J, .et al. , Int J Biochem Cell Biol, 2017, Jun;87:38-53 PMID: 28341201
-
ATM Inhibitor
KU-60019 是一种效力强大且特异性的 ATM 抑制剂,其 IC50 为 6.3 nM。- Erika Nakatsuka, .et al. , Transl Oncol, 2024, Sep 12:50:102119 PMID: 39270525
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Yuri Tozaki, .et al. , Cancers (Basel), 2023, Jan 25;15(3):735 PMID: 36765693
- Fu-Xing Gong, .et al. , Nucleic Acids Res, 2021, Sep 20;49(16):9342-9352 PMID: 34403458
- Hegedus C, .et al. , Cancers (Basel), 2019, Dec 18;12(1) PMID: 31861350
- Masaya Igase, .et al. , Mol Ther Oncolytics, 2019, vol 15 PMID: 31650025
- CHENGHUA LOU, .et al. , Oncol Lett, 2016, Jul; 12(1): 295-300 PMID: 27347141
-
PI3K Inhibitor
LY294002 是一种 PI3k 抑制剂(细胞 IC50 约为 10 μM)和 casein kinase II 抑制剂。- Yinhua Ni, .et al. , J Agric Food Chem, 2024, Jul 31;72(30):16708-16725 PMID: 39016108
- Yinhua Ni, .et al. , J Nutr Biochem, 2024, Mar:125:109569 PMID: 38185346
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Nahla E. El-Ashmawy, .et al. , Clin Phytosci, 2022, 8: 20
- Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
- Chien-Feng Li, .et al. , Cell Oncol (Dordr), 2021, Aug 2 PMID: 34339014
- Hiroharu Sakai, .et al. , Exp Ther Med, 2021, March 5 PMID: 33747195
- Cheng Zhou, .et al. , Cell Death Dis, 2021, Mar 3;12(3):231 PMID: 33658491
- Daniel Limonta, .et al. , J Infect Dis, 2019, 2019 PMID: 30799482
- Lv H, .et al. , J Cell Physiol, 2018, Oct 26 PMID: 30362547
- Hui Liang, .et al. , Sci Rep, 2017, 7: 40361 PMID: 28098170
-
PDK-1 inhibitor
OSU-03012 是一种新型的塞来昔布衍生物,不具有环氧合酶-2抑制活性,能够在多种癌症细胞类型中诱导凋亡。- Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
-
AKT Inhibitor
Palomid 529 是一种 TORC1/2 抑制剂,它针对 PI3K/Akt/mTOR 通路,具有广泛的抗血管生成和细胞增殖活性。 -
Akt inhibitor
Perifosine(亦称 KRX-0401)作为一种 Akt 抑制剂 和 PI3K 抑制剂 发挥作用。- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Bjune K, .et al. , PLoS One, 2019, Jun 19;14(6):e0218537 PMID: 31216345
- Kyoung-Jae Won, .et al. , Cell Death Dis, 2017, Jan; 8(1): e2554 PMID: 28079882
- Zhipeng Li, .et al. , Oncotarget, 2016, May 31; 7(22): 31892-31906 PMID: 26895469
- Won KJ, .et al. , Apoptosis., 2014, Jan;19(1):179-90 PMID: 24085402
-
PI3K Inhibitor
PI-103 是一种强效的、细胞渗透性的、ATP竞争性抑制剂,针对磷脂酰肌醇3激酶(PI3K)家族成员具有选择性,特别是对 DNA-PK、PI3K (p110α) 和 mTOR。- Diane Yang, .et al. , Diabetes, 2021, Oct;70(10):2419-2429 PMID: 34344789
- Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
-
PI3K Inhibitor
PIK-75 是一种咪唑吡啶类化合物,能够选择性地抑制 p110α,其 IC50 值为 5.8 nM。它对 p110γ 和 p110β 的抑制效果相对较弱,其 IC50 值分别为 0.076 μM 和 1.3 μM。- Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
-
PI4K inhibitor
PIK 93 选择性地抑制 III型 PI 4-激酶 酶,并通过小干扰 RNA 介导的单个 PI 4-激酶酶的下调。- Gavin Ka Yu Siu, .et al. , Sci Rep, 2016, 6: 23464 PMID: 27010100
-
mTOR Inhibitor
PP242 是一种强效且选择性的 mTOR 抑制剂,能够抑制 mTORC1 和 mTORC2。- Nobuyuki Kondo, .et al. , JCI Insight, 2023, Dec 22;8(24):e173688 PMID: 37917191
- Hiroshi Fukamachi, .et al. , J Exp Clin Cancer Res, 2019, 38:127 PMID: 30866995
- Fuse MJ, .et al. , Mol Cancer Ther, 2017, Oct;16(10):2130-2143 PMID: 28751539
-
MAO-B inhibitor
Quercetin 抑制多种酶系统,包括酪氨酸蛋白激酶、磷脂酶A2、磷酸二酯酶、线粒体ATP酶、PI 3-激酶和蛋白激酶C。 -
MAO-B inhibitor
槲皮素能够抑制多种酶系统,包括酪氨酸蛋白激酶、磷脂酶A2、磷酸二酯酶、线粒体ATP酶、PI 3-激酶和蛋白激酶C。 -
mTOR Inhibitors
Rapamycin(Sirolimus)通过抑制T细胞和B细胞对白细胞介素-2(IL-2)的反应,阻止它们的激活。- Yudong Li, .et al. , J Polym Sci, 2024, 62:2215-2230
- Ross van de Weterin, .et al. , Glia, 2024, Jun 20 PMID: 38899723
- Yuanqin Zhang, .et al. , Cancers (Basel), 2023, Dec 2;15(23):5691 PMID: 38067394
- Amnon Wittenstein, .et al. , PLoS Biol, 2023, Nov 9;21(11):e3002355 PMID: 37943958
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Hideki Kawasaki, .et al. , J Insect Physiol, 2023, Mar;145:104476 PMID: 36623750
- R Mahalakshmi, .et al. , Mol Biol Rep, 2022, Jan;49(1):463-476 PMID: 34739690
- Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
- Zhichao Wu, .et al. , Cells, 2021, Oct 27;10(11):2912 PMID: 34831135
- Matthew A Schaller, .et al. , JCI Insight, 2021, Sep 22;6(18):e148003 PMID: 34357881
- Matthew A. Schaller, .et al. , bioRxiv, 2021, January 21
- Ashley VanCleave, .et al. , Oncotarget, 2020, Jul 7; 11(27): 2597-2610 PMID: 32676162
- Y Huang, .et al. , Experimental and Therapeutic Medicine, 2020, 20(2), 736-747 PMID: 32742319
- Takuya Hirao, .et al. , Cancer Sci, 2018, Jan; 109(1): 121-131 PMID: 29121435
- Ya-Hui Chen, .et al. , J Diabetes Res, 2016, 2016: 1828071 PMID: 28004006
-
PI3K/mTOR inhibitor
Desmethyl-VS-5584 是 VS-5584 的去甲基类似物,VS-5584 是一种新型且高度选择性的 PI3K/mTOR 激酶抑制剂,用于治疗癌症。 -
PI3K Inhibitor
TGX-221 是一种强效、选择性且能渗透细胞的 PI3K p110β 抑制剂。- Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
- Mostafa Khater, .et al. , J Biol Chem, 2021, Jan-Jun, 296:100805 PMID: 34022220
- Mostafa Khater, .et al. , J Biol Chem, 2021, Jan 22;296:100325 PMID: 33493514
- Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
-
mTOR Inhibitor
WYE-354 是一种强效的细胞渗透性 mTOR 抑制剂(IC50 = 4.3 nM),能够阻断通过 mTOR 复合体 1 (mTORC1) 和 mTOR 复合体 2 (mTORC2) 的信号传导。它对 PI3K α 的抑制作用较弱(IC50 = 1026 nM),对其他激酶的抑制作用也较弱。 -
PI3K Inhibitor
XL147 是一种强效、选择性且可口服生物利用的小分子抑制剂,针对 I类磷脂酰肌醇3激酶(PI3K),具有潜在的抗肿瘤活性。- Yushi Hayashida, .et al. , Int J Cancer, 2016, Aug 1;139(3):700-11 PMID: 26989815
-
PI3K inhibitor
ZSTK474 是一种 ATP-竞争性抑制剂,针对 class I 磷脂酰肌醇 3 激酶 各种亚型。- Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
-
PI3K Inhibitor?€?
BKM120(NVP-BKM120)是一种生物可利用的特异性口服全类别I磷脂酰肌醇3激酶(PI3K)激酶抑制剂。- Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
- Danielle H Oh, .et al. , PNAS, 2023, Sep 5;120(36):e2306414120 PMID: 37643213
- Giri R. Gnawali, .et al. , Medicinal Chemistry Research, 2022, 31: 1154-1175
- Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
- Jeremiah J Bearss, .et al. , EMBO Rep, 2021, Apr 7;22(4):e50835 PMID: 33586867
- Takaaki Fujimura, .et al. , Cancer Biol Ther, 2020, Sep 1;21(9):863-870 PMID: 32835580
- Nachi Namatame, .et al. , Oncotarget, 2018, Oct 12; 9(80): 35141-35161 PMID: 30416685
- Jin H. Song, .et al. , Mol Cancer Ther, 2018, Dec;17(12):2710-2721 PMID: 30190422
- Saijo A, .et al. , Cancer Lett, 2018, May 1;421:17-27 PMID: 29448000
- Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
- Charles-André Philip, .et al. , BMC Cancer, 2017, 17: 638 PMID: 28886696
- Rogers HA, .et al. , Clin Cancer Res., 2013, Dec 1;19(23):6450-60 PMID: 24077346
-
mTOR/PI3K Inhibitor
GDC-0980 (RG7422) 是一种选择性的、高效的、口服生物利用度的抑制剂,针对 Class I PI3激酶 和 mTOR激酶 (TORC1/2),在体外的半抑制浓度(IC50)分别为 p110 α、β、δ 和 γ 亚型的 5、27、7 和 14 nM。- Kasun Wanigasooriya, .et al. , Front Oncol, 2022, Jul 4;12:920444 PMID: 35860583
-
PI3K/mTOR Inhibitor
PF-04691502 是一种 PI3K/mTOR 激酶抑制剂,同时也是针对 磷脂酰肌醇3激酶(PI3K) 和 哺乳动物雷帕霉素靶蛋白(mTOR) 的药物,作用于 PI3K/mTOR 信号通路。- Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
-
AKT inhibitor
GSK690693 是一种新型的 ATP 竞争性、低纳摩尔全谱 Akt 激酶抑制剂(IC50 值分别针对 Akt1、2 和 3 为 2、13 和 9 nM)。- Khan MI, .et al. , Prog Neuropsychopharmacol Biol Psychiatry, 2018, Mar 2;82:39-48 PMID: 9223784
-
AKT Inhibitor
Triciribine phosphate 抑制 Akt-1、-2 和 -3 的磷酸化、激活和信号传导,这可能导致抑制表达 Akt 的肿瘤细胞的增殖。 -
Akt inhibitor
A-674563 是一种 B/Akt 抑制剂,其 IC50 为 14 nM,同时也显示出对 PKA 和 CDK2 的抑制活性,其 IC50 分别为 16 nM 和 46 nM。- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Kobayashi T, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):1468-1475 PMID: 29196261
- Lin Xu, .et al. , Biochem Biophys Res Commun, 2016, Apr 15;472(4):662-8 PMID: 26920060
- Zou Y, .et al. , Biochem Biophys Res Commun, 2016, Aug 12;477(1):1-8 PMID: 26970307
-
mTOR/PI3K Inhibitor,
GSK2126458 是一种高效、口服生物利用度的 PI3Kα 和 mTOR 抑制剂,在体内药效动力学和肿瘤生长效能模型中均显示活性。